Scott D Spritzer1, Thomas P Bravo2, Joseph F Drazkowski3. 1. Department of Neurology, Mayo Clinic Health System, Eau Claire, WI, USA. 2. Department of Neurology, Loma Linda University, Loma Linda, CA, USA. 3. Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, USA.
Abstract
BACKGROUND: Antiepileptic drugs (AED) are often considered first line for monotherapy in treatment of patients with migraines, and also those with comorbid migraine and epilepsy. Topiramate, a newer generation AED, has broad mechanism of action and evidence of benefit in patients with either episodic or chronic migraine along with epilepsy, both generalized and focal. METHODS: Our goal is to review the relevant mechanisms of action along with any supportive evidence published to date on the use of topiramate (TPM) in patients with both migraine headache and epilepsy. CONCLUSIONS: There has been very little published to date on the use of TPM in patients diagnosed with both disorders. Despite this, TPM has been adopted as first line therapy in this patient population. Future studies investigating the effectiveness of this treatment strategy are warranted in order to determine the most effective use of this medication in patients diagnosed with migraine headaches and epilepsy.
BACKGROUND: Antiepileptic drugs (AED) are often considered first line for monotherapy in treatment of patients with migraines, and also those with comorbid migraine and epilepsy. Topiramate, a newer generation AED, has broad mechanism of action and evidence of benefit in patients with either episodic or chronic migraine along with epilepsy, both generalized and focal. METHODS: Our goal is to review the relevant mechanisms of action along with any supportive evidence published to date on the use of topiramate (TPM) in patients with both migraineheadache and epilepsy. CONCLUSIONS: There has been very little published to date on the use of TPM in patients diagnosed with both disorders. Despite this, TPM has been adopted as first line therapy in this patient population. Future studies investigating the effectiveness of this treatment strategy are warranted in order to determine the most effective use of this medication in patients diagnosed with migraine headaches and epilepsy.
Authors: James M Eales; Xiao Jiang; Xiaoguang Xu; Sushant Saluja; Artur Akbarov; Eddie Cano-Gamez; Michelle T McNulty; Christopher Finan; Hui Guo; Wojciech Wystrychowski; Monika Szulinska; Huw B Thomas; Sanjeev Pramanik; Sandesh Chopade; Priscilla R Prestes; Ingrid Wise; Evangelos Evangelou; Mahan Salehi; Yusif Shakanti; Mikael Ekholm; Matthew Denniff; Alicja Nazgiewicz; Felix Eichinger; Bradley Godfrey; Andrzej Antczak; Maciej Glyda; Robert Król; Stephen Eyre; Jason Brown; Carlo Berzuini; John Bowes; Mark Caulfield; Ewa Zukowska-Szczechowska; Joanna Zywiec; Pawel Bogdanski; Matthias Kretzler; Adrian S Woolf; David Talavera; Bernard Keavney; Pasquale Maffia; Tomasz J Guzik; Raymond T O'Keefe; Gosia Trynka; Nilesh J Samani; Aroon Hingorani; Matthew G Sampson; Andrew P Morris; Fadi J Charchar; Maciej Tomaszewski Journal: Nat Genet Date: 2021-05-06 Impact factor: 41.307